Combination therapy with recombinant human erythropoietin, interferon-α-2b and granulocyte- macrophage colony-stimulating factor in idiopathic myelofibrosis

Acta Haematologica

Volumn 96, Issue 2, 1996, Pages 79-82

  Bourantas, Konstantinos L ^a   Tsiara, Stavroula ^a   Christou, Leonidas ^a   Repousis, Panagiotis ^a   Konstantinidou, Pavlina ^a   Bai, Maria ^a   Seferiadis, Kostantin ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Erythropoietin; Granulocyte macrophage colony stimulating factor; Idiopathic; Interferon 2b; Myelofibrosis; Recombinant human

Indexed keywords

ALPHA2B INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; MIELOGEN; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TRANSFUSION; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; ERYTHROCYTE; FEMALE; FEVER; HUMAN; LEUKOCYTE COUNT; MALE; MYALGIA; MYELOFIBROSIS; PANCYTOPENIA; PRIORITY JOURNAL; SPLENOMEGALY; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; BETA 2-MICROGLOBULIN; BONE MARROW; ERYTHROPOIETIN; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMOGLOBINS; HUMANS; INTERFERON ALFA-2B; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MYELOFIBROSIS; PLATELET COUNT; RECOMBINANT PROTEINS; SPLEEN;

EID: 0030017058     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203720     Document Type: Article

References (24)

1. Pitcock JA, Reinhard EH, Justus BW, Mendelsohn RS: A clinical and pathological study of seventy cases of myelofibrosis. Ann Intern Med 1962;57:73-84.
2. Barosi G, Polino G: Chronic myelofibrosis with myeloid metaplasia: The spectrum of clinical syndromes. Haematologica 1987;72:553-562.
3. Silver RT: Interferon in the treatment of myeloproliferative disease. Semin Hematol 1990; 27(suppl 4):6-14.
4. Appelbaum FR: Introduction and overview of interferon alpha in myeloproliferative and hem-angiomatous diseases. Semin Hematol 1990; 27(suppl 3): 1-5.
5. Pagliuca A, Layton DM, Manoharan A, Gordon S, Green PJ, Mufti GJ: Myelofibrosis in primary myelodysplastic syndromes: A clinico-morphological study of 10 cases. Br J Haematol 1989;71:499-504.
6. Takahashi M, Koikcc T, Nagayama R, Fujiwa-ra M, Koyama S, Ohnishi M, Nakamori Y, Soga N, Aoki S, Tatewaki W, Wada K, Moriya-ma Y, Shibata A: Myelodysplastic syndrome with myelofibrosis: Myelodysplastic syndrome as a major primary disorder for acute myelofibrosis. Clin Lab Haematol 1991:13:17-23.
7. Dickstein JI, Vardiman IW: Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. Am J Clin Pathol 1993;99:513-515.
8. Mulder H. Stcenbcrg J. Haanen C: Clinical course in survival after elective splenectomy in 19 patients with primary myelofibrosis. Br J Haematol 1977,35:419.
9. Benbassat J, Penchass S: ‘Early' splenectomy and survival in agnogenic myeloid metaplasia: An analysis of 338 cases published since 1940. Acta Haematol 1981:65:189.
10. Zucherman KS: Myelodysplasia. Curr Opin Hematol 1993;1:183-188.
11. Estey E: Treatment of acute myelogenous leukemia and myelodysplastic syndromes. Semin Hematol 1995;32:132-151.
12. Barosi G, Libcrato LN, Guamone R: Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1993: 83:365-369.
13. Eschbach SW, Egrie LC, Dewing MR, Browne JK, Adamson JW: Correction of the anemia of cnd-stagc renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316:73-78.
14. Bourantas K: High-dose recombinant human erythropoietin and low-dose corticosteroids for treatment of anemia in paroxysmal nocturnal hemoglobinuria. Acta Haematol 1994:91:62-65.
15. Means RT. Krantz SB: Progress in understanding the pathogenesis of anemia of chronic disease. Blood 1992;80:1693-1697.
16. Silver RT: Intcrferon-a-2b: A new treatment for polycythemia vera. Ann Intern Med 1993; 119:1091-1092.
17. Wintrobe’s Clinical Hematology, Ed 9. Philadelphia, Lea & Febiger. 1993, p 2028.
18. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov R, Talpaz M: Chronic myelogenous leukemia: A concise update. Blood 1993:3:691-703.
19. Van Genderen PJJ, Michiels JJ: Primary thrombocythcmia: Diagnosis, clinical manifestation and management. Ann Hematol 1993; 671:57-62.
20. Barosi G, Liberato LN, Costa A, Ascari E: Cytoreductive effect of recombinant alpha-in-terferon in patients with myelofibrosis with myeloid metaplasia. Blut 1989;58:271-274.
21. Spiriti M, Latagliata R, Avvisati G, Battistel V, Montcfusco E, Spadca E, Petti M: Erythropoietin treatment of idiopathic myelofibrosis. Hac-matologica 1993;76:371-373.
22. Mohr B, Hermann R, Huhn D: Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis. Acta Haematol 1993:90:65-70.
23. Rowland P. Mirro J: Clinical applications of the hematopoietic growth factors. Curr Opin Hematol 1994;1:303-309.
24. Sieff CA: Hematopoietic cell proliferation and differentiation. Curr Opin Hematol 1994:1: 310-320.